Context Therapeutics (CNTX) Competitors $0.74 +0.04 (+5.19%) Closing price 04:00 PM EasternExtended Trading$0.75 +0.01 (+1.86%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. TLSA, CGC, ACB, VOR, SCPH, ZYBT, DSGN, MREO, DMAC, and NMRAShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Tiziana Life Sciences (TLSA), Canopy Growth (CGC), Aurora Cannabis (ACB), Vor Biopharma (VOR), scPharmaceuticals (SCPH), Zhengye Biotechnology (ZYBT), Design Therapeutics (DSGN), Mereo BioPharma Group (MREO), DiaMedica Therapeutics (DMAC), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Its Competitors Tiziana Life Sciences Canopy Growth Aurora Cannabis Vor Biopharma scPharmaceuticals Zhengye Biotechnology Design Therapeutics Mereo BioPharma Group DiaMedica Therapeutics Neumora Therapeutics Tiziana Life Sciences (NASDAQ:TLSA) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk. Does the media refer more to TLSA or CNTX? In the previous week, Context Therapeutics had 2 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 9 mentions for Context Therapeutics and 7 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.55 beat Context Therapeutics' score of 0.01 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TLSA or CNTX? Tiziana Life Sciences has a beta of -0.57, meaning that its share price is 157% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Do insiders & institutionals hold more shares of TLSA or CNTX? 14.0% of Context Therapeutics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 2.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, TLSA or CNTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$11.86MN/AN/AContext TherapeuticsN/AN/A-$26.73M-$0.36-2.05 Do analysts rate TLSA or CNTX? Context Therapeutics has a consensus target price of $5.25, suggesting a potential upside of 613.02%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is TLSA or CNTX more profitable? Tiziana Life Sciences' return on equity of 0.00% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Context Therapeutics N/A -38.80%-37.53% SummaryContext Therapeutics beats Tiziana Life Sciences on 7 of the 12 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.05M$2.46B$5.60B$9.83BDividend YieldN/A1.68%4.60%4.11%P/E Ratio-2.0522.0830.3025.73Price / SalesN/A681.30448.5696.46Price / CashN/A183.0237.7558.93Price / Book0.804.708.456.01Net Income-$26.73M$31.61M$3.25B$264.94M7 Day Performance5.34%3.82%4.01%2.77%1 Month Performance0.56%3.19%4.23%1.61%1 Year Performance-71.68%13.19%36.26%29.31% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics3.3035 of 5 stars$0.74+5.2%$5.25+613.0%-70.7%$66.05MN/A-2.057Short Interest ↓Analyst RevisionTLSATiziana Life Sciences0.6165 of 5 stars$2.46+11.8%N/A+56.6%$257.07MN/A0.008News CoverageGap UpHigh Trading VolumeCGCCanopy Growth0.6686 of 5 stars$1.58+26.4%N/A-75.9%$256.43M$225.65M-0.523,150Positive NewsEarnings ReportOptions VolumeAnalyst RevisionGap DownHigh Trading VolumeACBAurora Cannabis0.4744 of 5 stars$5.21+16.3%N/A-17.3%$252.91M$246.72M-27.421,130Analyst RevisionHigh Trading VolumeVORVor Biopharma2.2246 of 5 stars$1.99-3.9%$5.63+182.8%+143.3%$252.01MN/A-1.21140News CoverageAnalyst ForecastGap DownSCPHscPharmaceuticals4.4681 of 5 stars$4.66+0.6%$14.00+200.4%-3.0%$246.77M$36.33M-2.5730News CoverageEarnings ReportShort Interest ↓ZYBTZhengye BiotechnologyN/A$5.38+3.3%N/AN/A$245.74M$25.53M0.00278Positive NewsGap DownDSGNDesign Therapeutics0.1541 of 5 stars$4.82+12.6%N/A+22.9%$243.74MN/A-4.3040Earnings ReportGap DownHigh Trading VolumeMREOMereo BioPharma Group2.0245 of 5 stars$1.52-0.7%$7.20+373.7%-54.0%$243.27M$10M-21.7140News CoverageEarnings ReportAnalyst RevisionDMACDiaMedica Therapeutics1.7362 of 5 stars$4.58-1.9%$10.75+134.7%+67.6%$241.39MN/A-7.1620News CoverageEarnings ReportShort Interest ↑NMRANeumora Therapeutics2.8738 of 5 stars$1.44-1.4%$7.14+396.0%-86.2%$236.44MN/A-0.92108Analyst Revision Related Companies and Tools Related Companies TLSA Alternatives CGC Alternatives ACB Alternatives VOR Alternatives SCPH Alternatives ZYBT Alternatives DSGN Alternatives MREO Alternatives DMAC Alternatives NMRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access